Aptorum Group Past Earnings Performance
Past criteria checks 0/6
Aptorum Group has been growing earnings at an average annual rate of 11.5%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 15.6% per year.
Key information
11.5%
Earnings growth rate
18.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 15.6% |
| Return on equity | -28.2% |
| Net Margin | -654.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Aptorum Group GAAP EPS of -$0.05
Oct 03Is Aptorum Group (NASDAQ:APM) In A Good Position To Deliver On Growth Plans?
Jul 14
Aptorum Group: Advancing Oncology, Autoimmune & Infectious Disease Therapies
Feb 11Aptorum inks development agreement with Exeltis
May 06We Think Shareholders Should Be Aware Of Some Factors Beyond Aptorum Group's (NASDAQ:APM) Profit
Apr 26Do Institutions Own Aptorum Group Limited (NASDAQ:APM) Shares?
Jan 16Aptorum files for early-stage trial for ALS-4 in Canada
Dec 21Revenue & Expenses BreakdownBeta
How Aptorum Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -3 | 4 | 5 |
| 30 Sep 23 | 1 | -8 | 6 | 7 |
| 30 Jun 23 | 1 | -13 | 7 | 8 |
| 31 Mar 23 | 1 | -12 | 8 | 9 |
| 31 Dec 22 | 1 | -10 | 8 | 9 |
| 30 Sep 22 | 1 | -10 | 8 | 10 |
| 30 Jun 22 | 1 | -11 | 8 | 10 |
| 31 Mar 22 | 1 | -18 | 8 | 10 |
| 31 Dec 21 | 2 | -25 | 8 | 11 |
| 30 Sep 21 | 1 | -14 | 8 | 12 |
| 30 Jun 21 | 1 | -4 | 8 | 13 |
| 31 Mar 21 | 1 | 1 | 8 | 12 |
| 31 Dec 20 | 1 | 6 | 8 | 11 |
| 30 Sep 20 | 1 | -5 | 8 | 10 |
| 30 Jun 20 | 1 | -16 | 9 | 9 |
| 31 Mar 20 | 1 | -17 | 10 | 8 |
| 31 Dec 19 | 1 | -19 | 11 | 7 |
| 30 Sep 19 | 1 | -19 | 10 | 6 |
| 30 Jun 19 | 1 | -18 | 9 | 4 |
| 31 Mar 19 | 0 | -17 | 8 | 4 |
| 31 Dec 18 | 0 | -15 | 7 | 3 |
| 30 Sep 18 | 0 | -11 | 6 | 3 |
| 30 Jun 18 | 0 | -7 | 6 | 3 |
| 31 Mar 18 | 0 | -5 | 4 | 3 |
| 31 Dec 17 | 0 | -3 | 3 | 3 |
Quality Earnings: APM is currently unprofitable.
Growing Profit Margin: APM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: APM is unprofitable, but has reduced losses over the past 5 years at a rate of 11.5% per year.
Accelerating Growth: Unable to compare APM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: APM has a negative Return on Equity (-28.22%), as it is currently unprofitable.